Table 1.
Baseline clinical characteristics of patients before PSM.
| Characteristic* | Resection-based (n = 388) | Sorafenib-based (n = 108) | P-value |
|---|---|---|---|
| Age (y) | 0.064 | ||
| ≤50 | 215 (55.4) | 49 (45.4) | |
| >50 | 173 (44.6) | 59 (54.6) | |
| Gender | 0.831 | ||
| Female | 23 (6.0) | 7 (6.5) | |
| Male | 365 (94.0) | 101 (93.5) | |
| HBsAg | 0.675 | ||
| Negative | 64 (16.5) | 16 (14.8) | |
| Positive | 324 (83.5) | 92 (85.2) | |
| HBVDNA | 0.032 | ||
| ≤103 | 181 (46.6) | 63 (58.3) | |
| > 103 | 207 (53.4) | 45 (41.7) | |
| Cirrhosis | <0.001 | ||
| None or mild | 190 (49.0) | 23 (21.3) | |
| Moderate or severe | 198 (51.0) | 85 (78.7) | |
| Ascites | 0.542 | ||
| Absent or mild | 359 (92.5) | 98 (90.7) | |
| Moderate or severe | 29 (7.5) | 10 (9.3) | |
| PLT (10E9/L) | 0.192 | ||
| ≤100 | 37 (9.5) | 15 (13.9) | |
| >100 | 351 (90.5) | 93 (86.1) | |
| ALT (U/L) | 0.720 | ||
| ≤50 | 248 (63.9) | 67 (62.0) | |
| >50 | 140 (36.1) | 41 (38.0) | |
| AST (U/L) | 0.008 | ||
| ≤40 | 151 (38.9) | 27 (25.0) | |
| >40 | 237 (61.1) | 81 (75.0) | |
| ALB (g/L) | <0.001 | ||
| ≤40 | 117 (30.2) | 52 (48.1) | |
| >40 | 271 (69.8) | 56 (51.9) | |
| TBIL (μmol/L) | <0.001 | ||
| ≤20.5 | 335 (86.3) | 77 (71.3) | |
| >20.5 | 53 (13.7) | 31 (28.7) | |
| PT (s) | 0.094 | ||
| ≤13.5 | 323 (83.2) | 97 (89.8) | |
| >13.5 | 65 (16.8) | 11 (10.2) | |
| AFP (ng/ml) | 0.336 | ||
| ≤400 | 135 (34.8) | 43 (39.8) | |
| >400 | 253 (65.2) | 65 (60.2) | |
| Child-pugh score | <0.001 | ||
| 5 | 344 (88.7) | 82 (75.9) | |
| 6 | 39 (10.0) | 24 (22.2) | |
| >6 | 5 (1.3) | 2 (1.9) | |
| Number of tumor (s) | <0.001 | ||
| Single | 263 (67.8) | 35 (32.4) | |
| Multiple | 125 (32.2) | 73 (67.6) | |
| Tumor distribution | <0.001 | ||
| Uni-lobar | 351 (90.5) | 53 (49.1) | |
| Bi-lobar | 37 (9.5) | 55 (50.9) | |
| Size of largest nodule (cm) | 0.172 | ||
| <5 | 56 (14.4) | 23 (21.3) | |
| 5–10 | 214 (55.2) | 51 (47.2) | |
| >10 | 118 (30.4) | 34 (31.5) | |
| Tumor thrombus | |||
| Vp1 | 22 (5.7) | 1 (0.9) | <0.001 |
| Vp2 | 111 (28.6) | 9 (8.3) | |
| VP3 | 237 (61.1) | 57 (52.8) | |
| Vp4 | 18 (4.6) | 41 (38.0) | |
| Pre-treatment | |||
| None | 306 (78.9) | 40 (37.0) | |
| Surgery | 7 (1.8) | 12 (11.1) | |
| TACE | 54 (13.9) | 94 (87.0) | |
| RFA/PMCT | 6 (1.5) | 14 (13.0) | |
| HAIC | 15 (3.9) | 16 (14.8) | |
| Follow-up treatment | |||
| Surgery | 7 (1.8) | 3 (2.8) | |
| TACE | 169 (43.6) | 41 (38.0) | |
| RFA/PMCT | 51 (13.1) | 12 (11.1) | |
| TAI | 12 (3.1) | 15 (13.9) | |
| Radiotherapy | 7 (1.8) | 6 (5.6) | |
| Sorafenib | 25 (6.4) | – |
*
No. (%).
PSM, propensity score matching; HBsAg, hepatitis B surface antigen; PLT, blood platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; AFP, alpha fetoprotein; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; PMCT, percutaneous microwave coagulation therapy; HAIC, hepatic artery infusion chemotherapy.